Philip Low Email and Phone Number
Philip Low work email
- Valid
Philip Low personal email
Philip Low phone numbers
Philip S. Low is the Presidential Scholar in Drug Discovery and the Ralph C. Corley Distinguished Professor of Chemistry. Dr. Low has spent over >30 years exploring novel methods for targeted drug discovery, including target identification, drug design and synthesis, animal testing, and human clinical evaluation. He has published >500 scientific articles and has >360 US patents/patents pending. Eight drugs stemming from his research are currently undergoing human clinical trials and seven companies (Endocyte Inc., OnTarget Laboratories Inc., Novosteo Inc., Erythrocure Inc., Umoja Biopharma Inc., Morphimmune Inc. and Eradivir Inc.) have been founded to commercialize these discoveries. Dr. Low has received an NIH MERIT Award, the ACS Award for Cancer Research (Sosnovsky Award), the AACR Award for Outstanding Chemistry in Cancer Research, both of Purdue's awards for outstanding research (McCoy and Sigma Xi Awards), the University’s highest career achievement award (Morrill Award), and numerous other National and International awards. Dr. Low received his B.S. in Chemistry from Brigham Young University (1971) and his Ph.D. in Biochemistry from UCSD (1975).
-
Purdue Institute For Drug DiscoveryPurdue UniversityWest Lafayette, In, Us
-
Purdue Institute For Drug DiscoveryPurdue University 2013 - PresentWest Lafayette, In, UsWe are focusing on improving the quality of life for people around the world. As one of the preeminent drug discovery Institutes in the United States, we engage in drug discovery across disciplines and institutions, translate basic research into clinical applications, educate the next generation of researchers in drug discovery and commercialize innovations for the marketplace - all with the goal of developing new diagnostic tools and treatments for people in need.
-
Corley Distinguished Professor Of ChemistryPurdue University Aug 1976 - PresentWest Lafayette, In, Us
-
Co-Founder And DirectorUmoja Biopharma Feb 2019 - PresentSeattle, Wa, UsUmoja Biopharma Inc. is developing a sensitively controllable universal CAR T cell therapy for treatment of both liquid and solid tumor. With this technology, a single CAR T cell preparation can be used with appropriate bispecific adapters to treat virtually any cancer, while concurrently maintaining control over levels of cytokine release, degree of CAR T cell activation/exhaustion, and nature of tumor antigen to to attack. -
Founder And DirectorMorphimmune Jan 2020 - PresentWest Lafayette, Indiana, UsMorphImmune, Inc. addresses significant unmet medical needs by selectively targetingand reprogramming dysregulated immune cells that cause or promote disease. Immune cell types for which targeted therapies are under development include activated macrophages, T cells, antigen presenting cells, and activated fibroblasts. Diseases addressed using this approach include cancers, autoimmune, inflammatory, traumatic and fibrotic diseases. -
Co-Founder, Director And Chief Science OfficerEradivir Mar 2020 - PresentEradivir Inc. is designing, synthesizing, and testing in animal models and human clinical trials different targeted therapies for important viral diseases. The most advanced product in our pipeline is a targeted therapy for influenza virus infections that eliminates all free virus and virus-infected cells, even in late stage infections. Related therapies are also under development for HIV, hepatitis C and SARS-Cov-2 infections.
-
Co-Founder, Director And Chief Science OfficerErythrocure Inc. Jul 2018 - PresentErythroCure Inc. is developing novel therapies for both Plasmodium falciparum malaria and sickle cell disease. In each case, the therapy involves blocking an erythrocyte pathway that when activated leads to destabilization and eventual fragmentation of the erythrocyte membrane. This pathway is induced by the malaria parasite in preparation for its egress from the red cell, and blockade of the pathway prevents escape of the parasite from its RBC host. This pathway is also pathologically activated in sickle cells where it results in release of membrane-derived microparticles plus cell-free hemoglobin, both of which contribute to the vaso-occlusive events that cause the symptoms of sickle cell disease. Inhibition of the pathway in sickle cells suppresses development of disease symptoms. ErythroCure Inc. is developing drugs to prevent activation of this pathway in both sickle and malaria -infected erythrocytes.
-
Co-Founder And DirectorNovosteo Inc.. May 2017 - PresentWe design and develop targeted therapies to accelerate the rate of bone fracture repair. Applications lie not only in treating the 7 million bone fractures/year in the USA, but also in reducing the morbidity associated with bone reconstruction procedures, cancers that metastasize to bone, osteoporosis, arthritis, stabilization of orthopedic implants, and diabetes-associated bone destabilization.
-
Co-Founder And Chief Science OfficerOn Target Laboratories, Llc 2011 - PresentWest Lafayette, Indiana, UsOn Target Laboratories designs and develops tumor-targeted near infrared fluorescent dyes to enable the cancer surgeon to find and resect more malignant lesions than would be possible with current technologies. Moreover, to help the surgeon avoid damaging critical healthy tissues during surgeries, On Target Laboratories is also developing other colored near infrared fluorescent dyes that target and highlight nerves, ducts (ureters and bile duct) and blood vessels. -
Co-Founder, Chief Science Officer And Board MemberEndocyte Inc. Dec 1995 - Dec 2018West Lafayette, In, UsEndocyte Inc. is developing ligand targeted imaging and therapeutic agents to diagnose and treat multiple human cancers. By delivering the chemotherapeutic drug selectively to the maligant tissue, much of the usual toxicity associated with drug accumulation in healthy tissues can be avoided.
Philip Low Skills
Philip Low Education Details
-
Uc San DiegoBiochemistry -
Brigham Young UniversityChemistry
Frequently Asked Questions about Philip Low
What company does Philip Low work for?
Philip Low works for Purdue University
What is Philip Low's role at the current company?
Philip Low's current role is Purdue Institute for Drug Discovery.
What is Philip Low's email address?
Philip Low's email address is pl****@****due.edu
What is Philip Low's direct phone number?
Philip Low's direct phone number is +176549*****
What schools did Philip Low attend?
Philip Low attended Uc San Diego, Brigham Young University.
What skills is Philip Low known for?
Philip Low has skills like Drug Discovery, Lifesciences, Life Sciences, Biotechnology, Chemistry, Molecular Biology, Biochemistry, Protein Chemistry, Cell Biology, Cell Culture.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial